Stocks and Investing Stocks and Investing
Fri, March 18, 2022
Thu, March 17, 2022
Wed, March 16, 2022
Tue, March 15, 2022
Mon, March 14, 2022

Tiago Fauth Maintained (ASND) at Buy with Increased Target to $194 on, Mar 14th, 2022


Published on 2024-10-27 20:04:30 - WOPRAI, Tiago Fauth
  Print publication without navigation


Tiago Fauth of Credit Suisse, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $188 to $194 on, Mar 14th, 2022.

Tiago has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 1 agrees with Tiago's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022


These are the ratings of the 5 analyists that currently disagree with Tiago


  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $180 on, Monday, March 7th, 2022
  • Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $170 on, Thursday, March 3rd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $117 on, Thursday, March 3rd, 2022
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021